1
|
Arain F, Gullestad L, Nymo S, Kjekshus J, Cleland JG, Michelsen A, McMurray JJ, Wikstrand J, Aukrust P, Ueland T. Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA). Biomarkers 2016; 22:261-267. [PMID: 27325138 DOI: 10.1080/1354750x.2016.1204003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
CONTEXT AND OBJECTIVE To evaluate if YKL-40 can provide prognostic information in patients with ischemic heart failure (HF) and identify patients who may benefit from statin therapy. MATERIALS AND METHODS The association between serum YKL-40 and predefined outcome was evaluated in 1344 HF patients assigned to rosuvastatin or placebo. RESULTS YKL-40 was not associated with outcome in adjusted analysis. In YKL-40 tertile 1, an effect on the primary outcome (HR 0.50, p = 0.006) and CV death (HR 0.54, p = 0.040) was seen by rosuvastatin in adjusted analysis. CONCLUSIONS A beneficial modification of outcome was observed with statin therapy in patients with low YKL-40 levels.
Collapse
Affiliation(s)
- Fizza Arain
- a Department of Cardiology , Oslo University Hospital Rikshospitalet , Oslo , Norway.,b Research Institute of Internal Medicine , Oslo University Hospital Rikshospitalet , Oslo , Norway.,c K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research , University of Oslo , Oslo , Norway
| | - Lars Gullestad
- a Department of Cardiology , Oslo University Hospital Rikshospitalet , Oslo , Norway.,c K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research , University of Oslo , Oslo , Norway.,d Faculty of Medicine , University of Oslo , Oslo , Norway
| | - Ståle Nymo
- b Research Institute of Internal Medicine , Oslo University Hospital Rikshospitalet , Oslo , Norway
| | - John Kjekshus
- a Department of Cardiology , Oslo University Hospital Rikshospitalet , Oslo , Norway.,c K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research , University of Oslo , Oslo , Norway.,d Faculty of Medicine , University of Oslo , Oslo , Norway
| | - John G Cleland
- e Department of Cardiology , Hull York Medical School, University of Hull, Castle Hill Hospital , Kingston-upon-Hull, Glasgow , UK
| | - Annika Michelsen
- b Research Institute of Internal Medicine , Oslo University Hospital Rikshospitalet , Oslo , Norway
| | - John J McMurray
- f British Heart Foundation Glasgow Cardiovascular Research Centre , University of Glasgow , Glasgow , UK
| | | | - Pål Aukrust
- b Research Institute of Internal Medicine , Oslo University Hospital Rikshospitalet , Oslo , Norway.,d Faculty of Medicine , University of Oslo , Oslo , Norway.,g Sahlgrenska University Hospital , Gøteborg , Sweden.,h K.G. Jebsen Inflammatory Research Center , University of Oslo , Oslo , Norway.,i Section of Clinical Immunology and Infectious Diseases , Oslo University Hospital Rikshospitalet Oslo , Norway
| | - Thor Ueland
- b Research Institute of Internal Medicine , Oslo University Hospital Rikshospitalet , Oslo , Norway.,d Faculty of Medicine , University of Oslo , Oslo , Norway.,h K.G. Jebsen Inflammatory Research Center , University of Oslo , Oslo , Norway.,j K.G. Jebsen Thrombosis Research and Expertise Center , University of Tromsø , Tromsø , Norway
| |
Collapse
|
2
|
Strohbach A, Begunk R, Petersen S, Felix SB, Sternberg K, Busch R. Biodegradable Polymers Influence the Effect of Atorvastatin on Human Coronary Artery Cells. Int J Mol Sci 2016; 17:E148. [PMID: 26805825 PMCID: PMC4783882 DOI: 10.3390/ijms17020148] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2015] [Revised: 01/14/2016] [Accepted: 01/18/2016] [Indexed: 11/16/2022] Open
Abstract
Drug-eluting stents (DES) have reduced in-stent-restenosis drastically. Yet, the stent surface material directly interacts with cascades of biological processes leading to an activation of cellular defense mechanisms. To prevent adverse clinical implications, to date almost every patient with a coronary artery disease is treated with statins. Besides their clinical benefit, statins exert a number of pleiotropic effects on endothelial cells (ECs). Since maintenance of EC function and reduction of uncontrolled smooth muscle cell (SMC) proliferation represents a challenge for new generation DES, we investigated the effect of atorvastatin (ATOR) on human coronary artery cells grown on biodegradable polymers. Our results show a cell type-dependent effect of ATOR on ECs and SMCs. We observed polymer-dependent changes in IC50 values and an altered ATOR-uptake leading to an attenuation of statin-mediated effects on SMC growth. We conclude that the selected biodegradable polymers negatively influence the anti-proliferative effect of ATOR on SMCs. Hence, the process of developing new polymers for DES coating should involve the characterization of material-related changes in mechanisms of drug actions.
Collapse
Affiliation(s)
- Anne Strohbach
- Department of Internal Medicine B (Cardiology), University Medicine Greifswald, Ferdinand-Sauerbruch-Strasse, 17475 Greifswald, Germany.
- DZHK (German Centre for Cardiovascular Research), Partner Site Greifswald, University Medicine Greifswald, 17475 Greifswald, Germany.
| | - Robert Begunk
- Institute of Pharmacology, University Medicine Greifswald, Felix-Hausdorff-Strasse 3, 17477 Greifswald, Germany.
| | - Svea Petersen
- Faculty of Engineering and Informatics, Osnabrück University of Applied Sciences, Albrechtstrasse 30, 49076 Osnabrück, Germany.
| | - Stephan B Felix
- Department of Internal Medicine B (Cardiology), University Medicine Greifswald, Ferdinand-Sauerbruch-Strasse, 17475 Greifswald, Germany.
- DZHK (German Centre for Cardiovascular Research), Partner Site Greifswald, University Medicine Greifswald, 17475 Greifswald, Germany.
| | - Katrin Sternberg
- Research & Development, Aesculap AG, Am Aesculap Platz, 78532 Tuttlingen, Germany.
| | - Raila Busch
- Department of Internal Medicine B (Cardiology), University Medicine Greifswald, Ferdinand-Sauerbruch-Strasse, 17475 Greifswald, Germany.
- DZHK (German Centre for Cardiovascular Research), Partner Site Greifswald, University Medicine Greifswald, 17475 Greifswald, Germany.
| |
Collapse
|
3
|
Cifuentes RA, Cruz-Tapias P, Rojas-Villarraga A, Anaya JM. ZC3H12A (MCPIP1): molecular characteristics and clinical implications. Clin Chim Acta 2010; 411:1862-8. [PMID: 20807520 DOI: 10.1016/j.cca.2010.08.033] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2010] [Revised: 08/22/2010] [Accepted: 08/24/2010] [Indexed: 12/15/2022]
Abstract
BACKGROUND ZC3H12A is a gene whose absence is related to autoimmune disorders and to other phenotypical alterations. METHODS A comprehensive review of the structure, molecular functions and regulation of ZC3H12A gene and its protein MCPIP1 is done in order to understand their clinical implications. RESULTS ZC3H12A, at 1p34.3, has 9860bp, six exons and 61 described SNPs. Eleven are non-synonymous thus leading to changes in MCPIP1, the protein encoded by ZC3H12A. MCPIP1 is induced by MCP-1 and IL-1 whose signals are transduced through the NF-kβ and MAPkinase pathways. This protein acts as an RNAse by degrading chemokine transcripts such as IL-1 as well as its own mRNA and as a transcription factor by reducing the expression of other chemokines induced by NF-kβ such as MCP-1. It also up-regulates genes involved in several differentiation processes and apoptosis. Therefore, ZC3H12A is an equilibrium gatekeeper that not only regulates its own inducers but also controls the regulation by degrading its own mRNA. CONCLUSION Understanding ZC3H12A gives a comprehensive panorama that promises to improve our understanding of processes in which this gene is involved including autoimmune, infectious and cardiovascular diseases.
Collapse
Affiliation(s)
- Ricardo A Cifuentes
- Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia
| | | | | | | |
Collapse
|
5
|
von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther 2008; 121:227-52. [PMID: 19061914 DOI: 10.1016/j.pharmthera.2008.09.009] [Citation(s) in RCA: 258] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2008] [Accepted: 09/03/2008] [Indexed: 01/10/2023]
Abstract
Cardiac cachexia as a terminal stage of chronic heart failure carries a poor prognosis. The definition of this clinical syndrome has been a matter of debate in recent years. This review describes the ongoing discussion about this issue and the complex pathophysiology of cardiac cachexia and chronic heart failure with particular focus on immunological, metabolic, and hormonal aspects at the intracellular and extracellular level. These include regulators such as neuropeptide Y, leptin, melanocortins, ghrelin, growth hormone, and insulin. The regulation of feeding is discussed as are nutritional aspects in the treatment of the disease. The mechanisms of wasting in different body compartments are described. Moreover, we discuss several therapeutic approaches. These include appetite stimulants like megestrol acetate, medroxyprogesterone acetate, and cannabinoids. Other drug classes of interest comprise angiotensin-converting enzyme inhibitors, beta-blockers, anabolic steroids, beta-adrenergic agonists, anti-inflammatory substances, statins, thalidomide, proteasome inhibitors, and pentoxifylline.
Collapse
Affiliation(s)
- Stephan von Haehling
- Applied Cachexia Research, Department of Cardiology, Charité Medical School, Campus Virchow-Klinikum, Berlin, Germany.
| | | | | | | |
Collapse
|